Drugmakers & Drug Development Tools

Commercial medicines and the tools used to develop and manufacture them offer exposure to healthcare innovation rather than the crowded AI infrastructure cycle. Drugmakers in the basket have generally strengthened while technology hardware has weakened, making this a timely diversification candidate. Established treatment franchises and research infrastructure broaden the opportunity beyond obesity drugs, although pipeline setbacks, reimbursement pressure and stronger recent share prices remain risks. Launch basket (equal weight): ABBV, AMGN, MRK, LLY, JNJ, MRNA, TMO, GILD, PFE, BMY, REGN, VRTX Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.